"Our experimental drug can protect against all forms of Ebola known to harm people, suggesting that it will continue to protect people if the Ebola viruses evolve over time," said Geisbert.
The study, published in the journal Cell Host & Microbe, found that a two-antibody cocktail called MBP134 could fully protect nonhuman primates and ferrets against lethal Ebola virus infections caused by the Bundibugyo and Sudan strain as well as the deadliest Zaire strain that caused the 2013-16 epidemic in West Africa and the current outbreak in the Democratic Republic of Congo.
"Further studies exploring even lower doses could open the door to treatment via auto-injectors like the kind used for allergic reactions," Zeitlin said.
"The ability to quickly and efficiently provide protection against all Ebola viruses in a single dose would reduce the burden on health care workers in the field during outbreaks, especially in regions that have a less-developed infrastructure" he said.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)